{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":587,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":587,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"274f257c934d","filters":{"topic":"Lung Cancer Research Studies"}},"results":[{"id":"W1903523058","doi":"10.1038/nature14664","title":"Comprehensive genomic profiles of small cell lung cancer","year":2015,"lang":"en","type":"article","venue":"Nature","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2386,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Terry Fox Research Institute; Vancouver General Hospital","funders":"National Cancer Institute; National Institutes of Health; Stand Up To Cancer; Deutschen Konsortium für Translationale Krebsforschung; Associazione Italiana per la Ricerca sul Cancro; Bundesministerium für Bildung und Forschung; Deutsches Zentrum für Lungenforschung; European Regional Development Fund; Roy Castle Lung Cancer Foundation; European Commission; Universität zu Köln; Ministero della Salute; Deutsche Forschungsgemeinschaft; Genentech; Deutsche Krebshilfe","keywords":"Biology; Cancer research; Somatic cell; Gene; Chromothripsis; Cancer; Cyclin D1; Mutation; Suppressor; Mutant; Genetics; Tumor suppressor gene; Lung cancer; SMARCA4; Carcinogenesis; Genome instability; Gene expression; Cell cycle; Medicine; Pathology; DNA damage; DNA","retraction":null,"screen_n_in":null,"score":{"opus":0.03260873819400115,"gpt":0.3621605948796229,"spread":0.3295518566856218,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000675098,0.00009813132,0.0002482269,0.00006315692,0.00002247515,0.000004180368,0.00009864918,0.0003040969,0.00004573254],"category_scores_gemma":[0.00006367027,0.00007219856,0.00005113099,0.0001347769,0.00007255826,0.0000215494,0.00009585346,0.001043974,0.000008801389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002144794,"about_ca_system_score_gemma":0.0004144913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001473205,"about_ca_topic_score_gemma":0.00003222863,"domain_scores_codex":[0.9992061,0.00002318413,0.0001101146,0.0001655073,0.0002990871,0.0001960171],"domain_scores_gemma":[0.9990682,0.00003766154,0.00005234913,0.0001961702,0.0005251305,0.0001205031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009587551,0.0002003061,0.3055348,0.003488433,0.0005571432,0.0001065818,0.004088082,0.0000901996,0.1254526,0.0001660111,0.5574926,0.001864508],"study_design_scores_gemma":[0.01084178,0.0008916987,0.3684863,0.0009053388,0.0005649921,0.00003421986,0.002575258,0.0009367337,0.2170672,0.0001794146,0.3969644,0.0005527221],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9014273,0.08774244,0.000004365109,0.002149476,0.000291555,0.0005974743,0.00004896688,0.00003342117,0.007704981],"genre_scores_gemma":[0.9945033,0.0005434026,0.0008226721,0.0007241124,0.000322946,0.00004667831,0.00001305214,0.00001944242,0.003004358],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1605282,"threshold_uncertainty_score":0.4535605,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3118711697","doi":"10.1200/jco.20.01055","title":"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":824,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Internal medicine; Lung cancer; Hazard ratio; Placebo; Carboplatin; Oncology; Etoposide; Interim analysis; Gastroenterology; Surgery; Clinical trial; Cancer; Chemotherapy; Pembrolizumab; Immunotherapy; Confidence interval; Pathology; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.05157558275665592,"gpt":0.4224178008924977,"spread":0.3708422181358418,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000913235,0.0002260068,0.002457977,0.000260619,0.00005819132,0.00001602419,0.00009039621,0.0002190657,0.0001382168],"category_scores_gemma":[0.0008104297,0.000138396,0.0002205681,0.0006027556,0.0004495656,0.00008717416,0.0001239003,0.000757672,2.015397e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002155834,"about_ca_system_score_gemma":0.00143619,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005688373,"about_ca_topic_score_gemma":0.002309302,"domain_scores_codex":[0.9967782,0.000478527,0.001445373,0.0003636763,0.0006044324,0.0003298016],"domain_scores_gemma":[0.9942303,0.00132006,0.001381674,0.0002422147,0.002388414,0.000437363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01448972,0.0007126959,0.9722599,0.0001431889,0.008307744,0.001246904,0.0001962541,0.000138426,0.0002528963,0.00001340691,0.0003907502,0.001848164],"study_design_scores_gemma":[0.01802074,0.006885488,0.9658987,0.0001775067,0.006972529,0.00002679709,0.0002443213,0.00057346,0.0002598549,0.000004509907,0.0007911802,0.0001449177],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947345,0.002686,0.00003226438,0.001292471,0.000119839,0.0002759423,0.00005363185,0.000007258554,0.0007980717],"genre_scores_gemma":[0.9942281,0.003843591,0.000767523,0.0004302122,0.0001138374,0.000005144765,0.00002976813,0.00002479482,0.0005570564],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006361155,"threshold_uncertainty_score":0.5643623,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3030178583","doi":"10.1200/jco.20.00793","title":"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":759,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"William Osler Health System; University of Toronto","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Lung cancer; Hazard ratio; Clinical endpoint; Etoposide; Population; Gastroenterology; Progression-free survival; Oncology; Randomized controlled trial; Surgery; Confidence interval; Cancer; Chemotherapy; Immunotherapy; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.2457992469628378,"gpt":0.5415262119285564,"spread":0.2957269649657187,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.005244841,0.0003981017,0.004814168,0.000168824,0.00021227,0.00004157502,0.0003386023,0.0003767558,0.0003357744],"category_scores_gemma":[0.008400469,0.0002399045,0.0007938126,0.0002404395,0.0005051063,0.0001443477,0.0002151027,0.001704337,0.000004875828],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003914437,"about_ca_system_score_gemma":0.004925498,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002406484,"about_ca_topic_score_gemma":0.0004038313,"domain_scores_codex":[0.9939471,0.0007725986,0.003413784,0.0005643825,0.0007266207,0.0005755172],"domain_scores_gemma":[0.9821501,0.01296061,0.00224054,0.0002803896,0.001362264,0.001006126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9657739,0.002918787,0.002063878,0.0003012373,0.003208347,0.001795316,0.002831375,0.000238183,0.00009315171,0.00001607648,0.006124298,0.01463545],"study_design_scores_gemma":[0.9113879,0.05873763,0.0002772695,0.0001510778,0.001726911,0.0001295383,0.001205454,0.00405791,0.0002398543,0.00003817889,0.02182004,0.0002282677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9363154,0.007962205,0.001186703,0.04455121,0.000930682,0.008206927,0.00002671983,0.00003300234,0.000787209],"genre_scores_gemma":[0.9619196,0.02362641,0.0009992059,0.007373358,0.003560575,0.0004813375,0.000005579063,0.00006988573,0.001964027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05581884,"threshold_uncertainty_score":0.9999522,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2699278758","doi":"10.1016/s1470-2045(17)30318-2","title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":570,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Ottawa","funders":"Cancer Research UK","keywords":"Medicine; Chemoradiotherapy; Regimen; Lung cancer; Radiation therapy; Etoposide; Chemotherapy regimen; Internal medicine; Clinical endpoint; Performance status; Surgery; Randomized controlled trial; Chemotherapy; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.1504543789406404,"gpt":0.4667886956623838,"spread":0.3163343167217434,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001390903,0.0003914805,0.001743998,0.00008958431,0.0005141053,0.0001772488,0.001483928,0.0001913051,0.0002949709],"category_scores_gemma":[0.0003652237,0.0002486421,0.00006216083,0.0001584909,0.0007497154,0.0003399276,0.0004178891,0.0008797793,0.0000119118],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001314519,"about_ca_system_score_gemma":0.001328954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003104184,"about_ca_topic_score_gemma":0.004962564,"domain_scores_codex":[0.9968519,0.0005788234,0.0004807605,0.000675016,0.0004903194,0.0009231766],"domain_scores_gemma":[0.9971089,0.0004804021,0.0004262811,0.001425561,0.0002806334,0.0002781883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8900558,0.004505353,0.07243042,0.0002291954,0.0006105194,0.0001351326,0.002352051,0.000004183104,0.0006390958,0.00003632375,0.004513626,0.02448828],"study_design_scores_gemma":[0.9205495,0.01831436,0.01795355,0.0001304172,0.0002799715,0.000001899868,0.0001771046,0.0005043314,0.0004065362,0.000003507843,0.04135223,0.0003266058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807629,0.001177687,0.00001306254,0.005767933,0.001609707,0.006302029,0.0001364504,0.00006005325,0.004170154],"genre_scores_gemma":[0.9913784,0.002560527,0.0001973577,0.001450627,0.00174399,0.001488646,0.00006559295,0.00007466504,0.001040199],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05447687,"threshold_uncertainty_score":0.9999966,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2126709547","doi":"10.1158/1078-0432.ccr-11-3090","title":"Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":551,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Health Services","funders":"National Cancer Institute; U.S. Food and Drug Administration","keywords":"Medicine; Internal medicine; Oncology; Biomarker; Toxicity; Phases of clinical research; Clinical endpoint; Lung cancer; Clinical trial; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1977189728280281,"gpt":0.5160958239841599,"spread":0.3183768511561318,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003314531,0.0002812326,0.0008747581,0.0003912191,0.0002402557,0.00002482082,0.000268043,0.0001895922,0.0002439453],"category_scores_gemma":[0.0008549059,0.0002003439,0.00008864985,0.001049968,0.0008143578,0.0001666914,0.0007010311,0.001386093,0.000006023385],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007937654,"about_ca_system_score_gemma":0.0006288863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002941913,"about_ca_topic_score_gemma":0.001326184,"domain_scores_codex":[0.9948379,0.0007551244,0.0009432678,0.000720286,0.001572675,0.001170746],"domain_scores_gemma":[0.9964734,0.001131271,0.0001937432,0.0006253099,0.0009253419,0.0006508805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009951431,0.01845595,0.9496948,0.0005030707,0.0003830563,0.00002586403,0.00261672,0.000003619044,0.0004238939,0.000002335329,0.00350294,0.01443634],"study_design_scores_gemma":[0.04807788,0.02172265,0.9253666,0.0009142729,0.0002231519,8.018309e-7,0.001252373,0.0001285612,0.0005274646,0.000005671146,0.001510517,0.0002700842],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855751,0.009300147,0.000002127036,0.0005585026,0.0003725081,0.003621952,0.00004221023,0.00002624023,0.0005012303],"genre_scores_gemma":[0.9965475,0.001330977,0.00005051981,0.00007668811,0.0002454726,0.0007587486,0.00001272997,0.00006357252,0.0009138071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03812645,"threshold_uncertainty_score":0.8169787,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2065188377","doi":"10.1097/jto.0b013e31815bdc0d","title":"The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":547,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; TNM staging system; Lung cancer; Oncology; Stage (stratigraphy); Internal medicine; Lung cancer staging; Cancer; Radiology; Neoplasm staging; Mediastinoscopy","retraction":null,"screen_n_in":null,"score":{"opus":0.08743869756397145,"gpt":0.5345343729513192,"spread":0.4470956753873478,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01812823,0.0002718048,0.0009175928,0.0002716052,0.0006018018,0.00005586314,0.001056523,0.0001377371,0.0000173231],"category_scores_gemma":[0.002129544,0.0001235968,0.0004978371,0.0006764766,0.0002623894,0.0002409404,0.0002274175,0.001109247,2.08594e-8],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003835595,"about_ca_system_score_gemma":0.002892151,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002522609,"about_ca_topic_score_gemma":0.01291047,"domain_scores_codex":[0.994358,0.001020795,0.002212121,0.0003473572,0.001451625,0.0006101031],"domain_scores_gemma":[0.9856891,0.006765809,0.004591869,0.0004451213,0.002450157,0.00005793726],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004790222,0.0007581795,0.9167002,0.001340805,0.004060951,0.000006144891,0.01384015,0.003372207,0.002375315,0.0000753709,0.0119884,0.04069207],"study_design_scores_gemma":[0.01307681,0.001773938,0.6914884,0.005331052,0.01462792,0.000028471,0.08578396,0.1622085,0.01341223,0.0001525387,0.01154576,0.0005703658],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9278429,0.01468297,0.00456825,0.03844688,0.004485879,0.00944858,0.0002976914,0.00001166954,0.0002151563],"genre_scores_gemma":[0.9916513,0.003952499,0.0004070475,0.0003665723,0.001715688,0.001575,0.000003785368,0.00004549967,0.000282606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2252117,"threshold_uncertainty_score":0.9999885,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2128083415","doi":"10.1016/s1470-2045(13)70510-2","title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":526,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Juravinski Cancer Centre; Institut universitaire de cardiologie et de pneumologie de Québec; Alberta Cancer Foundation","funders":"Merck KGaA","keywords":"Medicine; Placebo; Chemoradiotherapy; Clinical endpoint; Internal medicine; Population; Lung cancer; Surgery; Phases of clinical research; Hazard ratio; Cancer; Clinical trial; Oncology; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.08993665752350942,"gpt":0.4353921749557403,"spread":0.3454555174322309,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001239928,0.0003629935,0.001476618,0.0001180661,0.0002105619,0.00005397545,0.0004187261,0.0002079282,0.001659552],"category_scores_gemma":[0.0001264969,0.0002314825,0.000277442,0.0002272158,0.0003277196,0.0001060063,0.0001269726,0.0005731338,0.00005828293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008988513,"about_ca_system_score_gemma":0.0009496404,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008858728,"about_ca_topic_score_gemma":0.0006373264,"domain_scores_codex":[0.9973777,0.0001880906,0.0005021088,0.0005138912,0.0003531889,0.001065045],"domain_scores_gemma":[0.9972728,0.001237916,0.0002392615,0.0007342948,0.0002779513,0.0002377458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9244736,0.0004978825,0.0001767278,0.0003841508,0.0008568019,0.00003740787,0.00164553,0.00001617181,0.003207437,0.00001886528,0.06547014,0.003215301],"study_design_scores_gemma":[0.8960482,0.00358879,0.00004652255,0.00005941636,0.0004150043,0.00000575931,0.0003205723,0.0009831968,0.004060821,0.00001776201,0.09421468,0.0002392472],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.945483,0.003169167,0.0005948705,0.02004842,0.001673564,0.02065391,0.00008144759,0.0001182908,0.008177314],"genre_scores_gemma":[0.8852832,0.005107578,0.002392628,0.006456194,0.01341065,0.06143029,0.00007886163,0.0002073963,0.02563322],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06019984,"threshold_uncertainty_score":0.9992531,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2018754160","doi":"10.1097/jto.0b013e3181b27799","title":"The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":492,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Texas MD Anderson Cancer Center; Barbara Ann Karmanos Cancer Institute; Wayne State University; Institut Gustave-Roussy; International Association for the Study of Lung Cancer; Eli Lilly and Company","keywords":"Medicine; Lung cancer staging; Lung cancer; Stage (stratigraphy); TNM staging system; Oncology; Internal medicine; Population; Malignancy; Cancer; Survival analysis; Radiology; Neoplasm staging; Mediastinoscopy","retraction":null,"screen_n_in":null,"score":{"opus":0.04987874132873191,"gpt":0.4713034335580689,"spread":0.421424692229337,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007843881,0.0002524697,0.0007816695,0.0002458098,0.0003864239,0.00003293295,0.0009893158,0.0001429447,0.000007377295],"category_scores_gemma":[0.001157961,0.0001046287,0.0002973474,0.0009005648,0.0004170285,0.000207576,0.0001160838,0.001216485,3.143426e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001477743,"about_ca_system_score_gemma":0.001824668,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006801299,"about_ca_topic_score_gemma":0.002215659,"domain_scores_codex":[0.9954409,0.00138431,0.001399751,0.0002855225,0.0009041046,0.0005854],"domain_scores_gemma":[0.9938818,0.002305694,0.002388116,0.0005459217,0.0008412851,0.00003715084],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009629119,0.001443453,0.4756871,0.006900562,0.001120418,0.0001383616,0.1071624,0.01094193,0.07475107,0.00111436,0.01894431,0.2921669],"study_design_scores_gemma":[0.01047512,0.004091182,0.7007277,0.01952861,0.004821634,0.0003270434,0.1242109,0.07518847,0.04636078,0.002985543,0.01033527,0.0009477127],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9051605,0.02719134,0.0009109547,0.06029793,0.0009523501,0.004805343,0.00006454324,0.000009088015,0.0006079361],"genre_scores_gemma":[0.9894455,0.008239009,0.0004464925,0.0005676538,0.000595763,0.0005577613,0.000001855445,0.00002438353,0.0001215656],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2912192,"threshold_uncertainty_score":0.5285089,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2905529840","doi":"10.1200/jco.18.01585","title":"<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":471,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Centre hospitalier universitaire de Québec","funders":"National Cancer Institute; Foundation Medicine; Pharmacyclics; Genentech; Incyte; Five Prime Therapeutics; Syndax Pharmaceuticals; Clovis Oncology; Exelixis; Alexion Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Gilead Sciences; Jounce Therapeutics; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Pfizer; Stop Cancer","keywords":"Medicine; T790M; Internal medicine; Oncology; Epidermal growth factor receptor; Lung cancer; Adenocarcinoma; Cancer; Cancer research; Gefitinib","retraction":null,"screen_n_in":null,"score":{"opus":0.1810748009524502,"gpt":0.5113336326705391,"spread":0.3302588317180889,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003272,0.0003088866,0.0026425,0.0002110082,0.0001096376,0.00002305778,0.000371719,0.0002263354,0.0002325084],"category_scores_gemma":[0.002720186,0.0001797019,0.0007562136,0.000217133,0.0008194145,0.0001111061,0.0002230507,0.001674496,0.00002476887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002802634,"about_ca_system_score_gemma":0.002013766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002521712,"about_ca_topic_score_gemma":0.0009147424,"domain_scores_codex":[0.9947681,0.0005017174,0.002875893,0.0004930042,0.0006821204,0.0006791409],"domain_scores_gemma":[0.9935991,0.003147676,0.0009527082,0.0003777224,0.0006528845,0.001269877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004857719,0.0007756505,0.9334382,0.0001164209,0.0007612116,0.001191509,0.0002961761,7.07167e-7,0.000105216,0.00001982421,0.01597982,0.04245757],"study_design_scores_gemma":[0.01164517,0.0165037,0.7178852,0.0001418065,0.0008761288,0.0004548158,0.0002086677,0.0000429232,0.0004584961,0.00005306666,0.2515515,0.0001785561],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9171441,0.002688064,0.00008458042,0.07166685,0.00256812,0.0007512537,0.0000181533,0.00002288521,0.005055993],"genre_scores_gemma":[0.9626956,0.00327013,0.001261252,0.02711273,0.003714273,0.00002394108,4.323712e-7,0.00005630415,0.001865327],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2355717,"threshold_uncertainty_score":0.732803,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2995889981","doi":"10.1016/j.jtho.2019.12.109","title":"Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":438,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"Merck Sharp and Dohme; EMD Serono; Genentech; National Institutes of Health; Eli Lilly and Company; Ono Pharmaceutical; National Cancer Institute; Servier; Daiichi-Sankyo; Puma Biotechnology; AbbVie; Aminex Therapeutics; Roche; Celgene; Novartis; Meso Scale Diagnostics; Sanofi; MedImmune; Merck; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; PharmaMar; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Pembrolizumab; Oncology; Internal medicine; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.05916321030402624,"gpt":0.4761060156971092,"spread":0.416942805393083,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009996665,0.0002358559,0.001218851,0.0001999744,0.00004100835,0.00001304516,0.0002058694,0.00006152418,0.00006456341],"category_scores_gemma":[0.001351026,0.0000961398,0.00009351825,0.0003036593,0.0003534702,0.000143763,0.0001491277,0.0005562214,0.000003563391],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002783923,"about_ca_system_score_gemma":0.0006267462,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008047243,"about_ca_topic_score_gemma":0.0005026085,"domain_scores_codex":[0.9973777,0.0004771674,0.0009159373,0.0002610591,0.000661843,0.0003062979],"domain_scores_gemma":[0.9961249,0.001755912,0.0008028324,0.0003312647,0.0008797534,0.0001053543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5161662,0.001325251,0.2688271,0.0004311561,0.002822053,0.0005481734,0.01552558,0.00004368871,0.00008932441,0.00000121594,0.00259225,0.1916281],"study_design_scores_gemma":[0.03753588,0.04060886,0.9068954,0.003164282,0.0008380639,0.000166499,0.004564982,0.00005816817,0.0002884336,0.000127878,0.005507253,0.0002443253],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.979326,0.01317492,0.000003813431,0.005980822,0.0003417527,0.0010635,0.00005762321,0.000005434149,0.0000461781],"genre_scores_gemma":[0.9892213,0.008209273,0.001575416,0.000432778,0.0002151885,0.00002653432,0.000004715879,0.00002429955,0.0002905317],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6380683,"threshold_uncertainty_score":0.3920467,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3132559292","doi":"10.1016/j.jtho.2021.02.009","title":"Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"Merck Sharp and Dohme; Ono Pharmaceutical; PharmaMar; Shionogi; Astellas Pharma; Daiichi-Sankyo; Cancer Research UK; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Amgen; Boehringer Ingelheim; Taiho Pharmaceutical; F. Hoffmann-La Roche; Chugai Pharmaceutical; Roche; Novartis; AbbVie; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Topotecan; Second line; Oncology; Internal medicine; Phase (matter); First line; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.0525605755118861,"gpt":0.4658585770188332,"spread":0.4132980015069471,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001561439,0.0001836568,0.001101548,0.0001513829,0.00008508181,0.0000163704,0.0002134657,0.00007917306,0.0001922984],"category_scores_gemma":[0.000979495,0.0001042106,0.00007347934,0.0004318369,0.00028234,0.00008308174,0.0001348997,0.0007875119,0.000001669462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004333774,"about_ca_system_score_gemma":0.001521536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004088638,"about_ca_topic_score_gemma":0.001579261,"domain_scores_codex":[0.9972834,0.0006778593,0.0009611368,0.0002694122,0.0005422854,0.0002658923],"domain_scores_gemma":[0.9965735,0.001574619,0.0006216596,0.0003979636,0.0006810997,0.0001511565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.523316,0.0164172,0.03199019,0.0001589098,0.005002263,0.01249939,0.02163609,0.000267819,0.02436025,0.00002692341,0.003938362,0.3603866],"study_design_scores_gemma":[0.1672179,0.07160321,0.6943872,0.001064008,0.0007847008,0.001927138,0.01610982,0.0001359383,0.02164434,0.0003263006,0.02446849,0.0003309374],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826578,0.002608706,0.00001605716,0.01323113,0.0001576482,0.0007051118,0.00005726207,0.000006998792,0.0005593207],"genre_scores_gemma":[0.9968764,0.001094153,0.0009373005,0.0004121331,0.0003567357,0.000008017928,0.0000139577,0.00001849465,0.0002828092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.662397,"threshold_uncertainty_score":0.4249584,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165132221","doi":"10.1200/jco.2002.02.108","title":"Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer","year":2002,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Chemotherapy; Lung cancer; Clinical trial; Cancer; Placebo; Oncology; Surgery; Gastroenterology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.178127568875417,"gpt":0.4985255809277916,"spread":0.3203980120523746,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.0297347,0.0001673445,0.0036044,0.0001981899,0.00006853603,0.000007162283,0.0001782356,0.0001359793,0.00005426414],"category_scores_gemma":[0.02042614,0.00007535337,0.000338297,0.0003923695,0.001091987,0.00005437798,0.00007774579,0.0004021174,2.495602e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007129387,"about_ca_system_score_gemma":0.004041051,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01022799,"about_ca_topic_score_gemma":0.08033637,"domain_scores_codex":[0.9898179,0.004807645,0.003915358,0.0002534258,0.000977283,0.0002284244],"domain_scores_gemma":[0.9757913,0.01832875,0.002923497,0.0001662754,0.002631935,0.0001581971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9365627,0.003335537,0.05125588,0.00009506011,0.002100074,0.000003990027,0.0006396473,0.00009423026,0.00001228728,0.00001391217,0.0004121388,0.005474587],"study_design_scores_gemma":[0.9350531,0.02173613,0.04103971,0.0002757648,0.0007529698,9.344782e-7,0.00003163455,0.00008900388,0.00007727125,0.00002722772,0.0008581433,0.00005817745],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9706736,0.001182947,0.00001806581,0.01367384,0.000639472,0.01363388,0.00006289367,0.000001156115,0.0001141957],"genre_scores_gemma":[0.9907297,0.007216901,0.0001804002,0.0001558299,0.0007875434,0.0006308205,0.000001188717,0.00002296911,0.0002746865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07010838,"threshold_uncertainty_score":0.9990923,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045410673","doi":"10.1200/jco.2003.10.089","title":"Continued Cigarette Smoking by Patients Receiving Concurrent Chemoradiotherapy for Limited-Stage Small-Cell Lung Cancer Is Associated With Decreased Survival","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Lung cancer; Toxicity; Etoposide; Chemotherapy; Cyclophosphamide; Vincristine; Chemoradiotherapy; Radiation therapy; Stage (stratigraphy); Surgery; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.1012839381682515,"gpt":0.4610338190641434,"spread":0.3597498808958919,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004089731,0.0002467746,0.002076658,0.0001006335,0.0001073787,0.00002319798,0.0001928912,0.0003483809,0.0001545401],"category_scores_gemma":[0.01029783,0.0001732832,0.0004320875,0.0002210078,0.0002266302,0.00008530592,0.00002715704,0.001125102,3.73558e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009896177,"about_ca_system_score_gemma":0.00236145,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003831959,"about_ca_topic_score_gemma":0.0001263142,"domain_scores_codex":[0.9960064,0.0006684084,0.001740564,0.0003245445,0.0007096218,0.0005504768],"domain_scores_gemma":[0.9902838,0.004929038,0.002284334,0.0001819705,0.001801839,0.0005189767],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003435765,0.001954574,0.9139649,0.0001186177,0.003254876,0.0000794204,0.0002811224,0.000004391557,0.0001573869,0.00000720017,0.05527676,0.02146501],"study_design_scores_gemma":[0.1430721,0.02598489,0.4828789,0.001722012,0.003240914,0.00001887611,0.000346622,0.0005444625,0.003366476,0.00002102708,0.338148,0.000655802],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883922,0.003701316,0.000527214,0.003232257,0.001533505,0.000895571,0.00007419566,0.00001831555,0.001625453],"genre_scores_gemma":[0.9904733,0.002645269,0.0005098869,0.004156386,0.0005235873,0.0000552625,0.00001826891,0.00006377316,0.001554228],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.431086,"threshold_uncertainty_score":0.9980388,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3105254545","doi":"10.1158/1078-0432.ccr-20-2845","title":"AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":238,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Digital Payment Technologies (Canada)","funders":"Amgen","keywords":"Cancer research; Medicine; Cell; Lung cancer; Ligand (biochemistry); Small molecule; T cell; Oncology; Internal medicine; Receptor; Chemistry; Immunology; Immune system","retraction":null,"screen_n_in":null,"score":{"opus":0.307856614907692,"gpt":0.5039285427276453,"spread":0.1960719278199533,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.008414973,0.0004724069,0.001931319,0.0003635692,0.0002503977,0.00006347625,0.0004281913,0.0005300268,0.0005858615],"category_scores_gemma":[0.005570857,0.0004057207,0.0003724127,0.001516273,0.001683693,0.0002195909,0.001215853,0.004980204,0.00002283393],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005223888,"about_ca_system_score_gemma":0.00360205,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01001491,"about_ca_topic_score_gemma":0.003776318,"domain_scores_codex":[0.9899285,0.002654405,0.001919322,0.001853915,0.002089351,0.001554441],"domain_scores_gemma":[0.9906326,0.00511405,0.0002903727,0.0009389529,0.001360541,0.001663464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03532979,0.007590272,0.7524678,0.01477039,0.001665336,0.003248862,0.006367546,0.002654885,0.04844612,0.0006205225,0.06865942,0.05817907],"study_design_scores_gemma":[0.0637829,0.01073352,0.658531,0.004376822,0.001060957,0.00002944825,0.00396605,0.2149931,0.02572845,0.002067587,0.01188718,0.002842974],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.939313,0.0342399,0.0001818381,0.02076831,0.0003396539,0.002823093,0.0002339373,0.00009549858,0.002004766],"genre_scores_gemma":[0.9560607,0.03925446,0.0006836053,0.001125243,0.001112426,0.0005331397,0.00001935935,0.0001069769,0.001104078],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2123382,"threshold_uncertainty_score":0.9998395,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3030999222","doi":"10.1001/jamaoncol.2020.1271","title":"Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases","year":2020,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Université de Sherbrooke","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences","keywords":"Medicine; Radiosurgery; Interquartile range; Lung cancer; Radiation therapy; Brain metastasis; Internal medicine; Prophylactic cranial irradiation; Oncology; Cohort; Retrospective cohort study; Cancer; Metastasis; Conventional PCI","retraction":null,"screen_n_in":null,"score":{"opus":0.09586448013135285,"gpt":0.4261814842082574,"spread":0.3303170040769045,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002821763,0.0002014821,0.0008492894,0.0001431024,0.00008395426,0.00001197047,0.0001517033,0.000160803,0.0008393807],"category_scores_gemma":[0.004848471,0.0001708646,0.0002230457,0.0003271603,0.0001342346,0.00007746834,0.0000625632,0.0002444988,0.000004691682],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001051446,"about_ca_system_score_gemma":0.001680868,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001871494,"about_ca_topic_score_gemma":0.0003822999,"domain_scores_codex":[0.9975182,0.0005329308,0.0004710554,0.0004133064,0.0006454981,0.000418981],"domain_scores_gemma":[0.9958144,0.002590252,0.00025631,0.0002501193,0.0008794246,0.0002094865],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0032107,0.0003394235,0.007380934,0.001447448,0.001161245,0.00003222701,0.002334056,0.001033238,0.02289438,0.00002783545,0.855301,0.1048375],"study_design_scores_gemma":[0.01976219,0.003897871,0.003889667,0.0001840042,0.001069777,0.00001213299,0.0002545069,0.05200739,0.01290083,0.00006061726,0.9057356,0.0002254359],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.2455751,0.03400484,0.003082583,0.7101889,0.0004829718,0.004642719,0.000932708,0.00009288054,0.0009972929],"genre_scores_gemma":[0.9108083,0.003017512,0.009882783,0.06140883,0.005578314,0.005866725,0.0007765747,0.0002197363,0.002441268],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.6652332,"threshold_uncertainty_score":0.919063,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137119609","doi":"10.1016/j.ijrobp.2013.02.033","title":"Decline in Tested and Self-Reported Cognitive Functioning After Prophylactic Cranial Irradiation for Lung Cancer: Pooled Secondary Analysis of Radiation Therapy Oncology Group Randomized Trials 0212 and 0214","year":2013,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":197,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Lung cancer; Randomized controlled trial; Prophylactic cranial irradiation; Radiation therapy; Radiation oncology; Internal medicine; Surgery; Oncology; Conventional PCI","retraction":null,"screen_n_in":null,"score":{"opus":0.03081488678861966,"gpt":0.4027891035192069,"spread":0.3719742167305872,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003611898,0.0002428286,0.001955881,0.0008416504,0.00007533038,0.00004181096,0.0001091348,0.0002551879,0.0001359058],"category_scores_gemma":[0.004369176,0.0001924463,0.000381417,0.0004946314,0.0002826327,0.0004704359,0.00004951,0.0004237013,5.913977e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009021777,"about_ca_system_score_gemma":0.0009730794,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003366657,"about_ca_topic_score_gemma":0.0001045694,"domain_scores_codex":[0.9960455,0.00121736,0.001818365,0.0003323668,0.0003381115,0.0002483477],"domain_scores_gemma":[0.9895051,0.005788777,0.002690233,0.0000940544,0.00179364,0.0001282296],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05413388,0.0007737661,0.4504627,0.0000716439,0.02043061,0.00001750421,0.001955635,0.0002274076,0.003977833,0.0001803342,0.0001317338,0.4676369],"study_design_scores_gemma":[0.2428494,0.003057487,0.6852872,0.0001284662,0.007845868,0.00006181963,0.0002739408,0.05644678,0.0007298458,0.002256146,0.0007881208,0.0002749508],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9770674,0.007844086,0.007588621,0.004047428,0.0008475912,0.002421582,0.0001019672,0.00002348778,0.00005787088],"genre_scores_gemma":[0.9870308,0.008723648,0.001468922,0.0008700871,0.001057102,0.0006072152,0.0002048626,0.00002479833,0.00001257187],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.467362,"threshold_uncertainty_score":0.7847733,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2129638180","doi":"10.1200/jco.2007.12.3083","title":"Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Vandetanib; Medicine; Internal medicine; Placebo; Gastroenterology; Oncology; Cancer; Phases of clinical research; Chemotherapy; Surgery; Pathology; Sorafenib","retraction":null,"screen_n_in":null,"score":{"opus":0.2888795793822542,"gpt":0.5751775702922032,"spread":0.286297990909949,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02533067,0.0002573171,0.002976155,0.0003577239,0.00008141948,0.000007648467,0.0002267897,0.0002252886,0.0002631452],"category_scores_gemma":[0.01004469,0.0001384628,0.0001856161,0.0006172502,0.000208965,0.0001645301,0.00007179016,0.0009513591,1.961269e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001411894,"about_ca_system_score_gemma":0.01616834,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.0197544,"about_ca_topic_score_gemma":0.6925155,"domain_scores_codex":[0.9893242,0.003090169,0.00539221,0.0003986223,0.001411468,0.0003833211],"domain_scores_gemma":[0.988769,0.005703026,0.003240072,0.0002121707,0.001642205,0.000433515],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5027769,0.02059345,0.4430085,0.00003083521,0.001228239,0.0001774687,0.00171285,0.0000714317,0.0001395533,1.424959e-7,0.00120857,0.02905208],"study_design_scores_gemma":[0.18923,0.181043,0.6173336,0.0001913615,0.0003939892,0.000007609947,0.001187575,0.00008715585,0.0001004304,0.000001103045,0.01027777,0.0001464345],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916983,0.0001928699,0.00006169825,0.0021736,0.001737076,0.004066242,0.00004566471,0.000004990225,0.00001955124],"genre_scores_gemma":[0.9961205,0.0004947144,0.0003322954,0.001233511,0.001310997,0.0001911922,0.000002569394,0.00002936597,0.0002848125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6727611,"threshold_uncertainty_score":0.9982941,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2995682899","doi":"10.1200/jco.19.02748","title":"Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Guideline; Lung cancer; Stage (stratigraphy); Positron emission tomography; Magnetic resonance imaging; Radiology; Randomized controlled trial; Medical physics; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1489323932712365,"gpt":0.5650323579464293,"spread":0.4160999646751927,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00419608,0.0001761304,0.001780862,0.0001113692,0.00002968564,0.000009877594,0.0001876443,0.0002501133,0.001683471],"category_scores_gemma":[0.003987863,0.0001063232,0.00056069,0.0001653973,0.000270781,0.0001271789,0.0001083026,0.001366106,0.00006490022],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004564239,"about_ca_system_score_gemma":0.002716759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008119062,"about_ca_topic_score_gemma":0.0001459798,"domain_scores_codex":[0.9958408,0.0006046519,0.002276987,0.0002539042,0.0006642333,0.0003593538],"domain_scores_gemma":[0.9935605,0.002438542,0.001255586,0.0002329389,0.002178867,0.0003335529],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01495941,0.0006860932,0.8467899,0.00004645767,0.00159762,0.0005160897,0.0002468149,0.0000137159,0.0001361094,0.00004682213,0.06997722,0.06498377],"study_design_scores_gemma":[0.01025511,0.009152634,0.6217261,0.0002407058,0.00009709634,0.00009473541,0.0001902713,0.0001763659,0.00006847803,0.0001037506,0.35777,0.0001247762],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9016781,0.0187802,0.0001631152,0.06574206,0.003451759,0.0006227694,0.00001909447,0.00001466923,0.009528265],"genre_scores_gemma":[0.9641938,0.019612,0.001183607,0.01149544,0.001978858,0.00002889677,0.000001985105,0.00002529037,0.00148015],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2877928,"threshold_uncertainty_score":0.9992291,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2113396130","doi":"10.1007/s13277-012-0379-2","title":"EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays","year":2012,"lang":"en","type":"article","venue":"Tumor Biology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"University of Nottingham","keywords":"Medicine; Lung cancer; Autoantibody; Internal medicine; Population; Cancer; Lung; Prospective cohort study; Oncology; Immunology; Gastroenterology; Pathology; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.068781475045296,"gpt":0.4493550002952464,"spread":0.3805735252499504,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009689506,0.0001888179,0.0005257065,0.0000469537,0.0001286042,0.00000749939,0.0001497197,0.0001385553,0.006830124],"category_scores_gemma":[0.004018353,0.0001388733,0.0001779516,0.0001531047,0.0007100079,0.0001197001,0.0002297185,0.000571958,0.0004055375],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001170685,"about_ca_system_score_gemma":0.0002789591,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001107715,"about_ca_topic_score_gemma":0.00001063459,"domain_scores_codex":[0.9979846,0.0002109503,0.0004536627,0.0003865537,0.0001857713,0.0007784388],"domain_scores_gemma":[0.9976115,0.001443293,0.00011423,0.0004090345,0.0001737259,0.0002481943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002248628,0.0005671934,0.8458843,0.00007069536,0.00019802,0.00002112256,0.00008417683,8.094097e-9,0.002622411,0.001011834,0.1474866,0.001828841],"study_design_scores_gemma":[0.001342869,0.0007225108,0.8263884,0.00003535955,0.00007386013,0.00009867734,0.00004707808,0.0001682881,0.0003479884,0.0004649175,0.1701541,0.0001559297],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8742153,0.007750087,0.0009629588,0.01154356,0.003853361,0.002917769,0.005964357,0.000896523,0.09189605],"genre_scores_gemma":[0.9932024,0.0001137455,0.001802894,0.001421626,0.001912431,0.0001128228,0.0005778061,0.00002178112,0.0008345203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.118987,"threshold_uncertainty_score":0.9940777,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125430981","doi":"10.1200/jco.2005.05.3181","title":"Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis","year":2006,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":184,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Etoposide; Radiation therapy; Chemotherapy; Vincristine; Lung cancer; Hazard ratio; Prophylactic cranial irradiation; Internal medicine; Cyclophosphamide; Surgery; Oncology; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.3082106847351426,"gpt":0.571832692282891,"spread":0.2636220075477484,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.01280296,0.0008737782,0.03509131,0.0006812628,0.0000897203,0.00005583249,0.0003722429,0.0007951484,0.0001070687],"category_scores_gemma":[0.002345829,0.0004454679,0.01250398,0.00063139,0.0008073544,0.0001038804,0.00008886476,0.001868677,3.217651e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001892788,"about_ca_system_score_gemma":0.005339087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002250731,"about_ca_topic_score_gemma":0.003167203,"domain_scores_codex":[0.979696,0.008721171,0.009151192,0.000973159,0.000763135,0.0006953898],"domain_scores_gemma":[0.9648432,0.02551944,0.007262157,0.0005788337,0.0007827793,0.001013659],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6397353,0.005061639,0.009834375,0.003207626,0.3008286,0.0003978024,0.00004883595,0.00006789031,3.710756e-8,0.000002257618,0.0005225494,0.04029305],"study_design_scores_gemma":[0.4765041,0.005889667,0.001416561,0.0005537746,0.4696934,0.000002985741,0.000002367314,0.003296693,2.362695e-8,0.00000403908,0.04240127,0.0002350799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0183379,0.9637111,0.0005565095,0.003668854,0.0006781653,0.01272454,0.0002882673,0.00001656874,0.00001803779],"genre_scores_gemma":[0.00169604,0.9902951,0.002133314,0.000507145,0.0014867,0.003025904,0.00007938927,0.00008946298,0.0006869843],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1688648,"threshold_uncertainty_score":0.9997997,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2586885021","doi":"10.1016/j.jtho.2016.01.012","title":"Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?","year":2016,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Cancer Research UK","keywords":"Cancer research; Targeted therapy; Aurora kinase; Medicine; Wnt signaling pathway; Receptor tyrosine kinase; Tyrosine kinase; Biology; Kinase; Bioinformatics; Cancer; Signal transduction; Cell cycle; Receptor; Internal medicine; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.04773074826963877,"gpt":0.530468196576259,"spread":0.4827374483066202,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001324477,0.0005776187,0.004884224,0.0009841401,0.00006081026,0.00000998082,0.0004289555,0.0008755943,0.00008827462],"category_scores_gemma":[0.0004857642,0.0003378231,0.0004871783,0.0004458719,0.0004481901,0.00007129926,0.0001779917,0.001603438,0.000001640663],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002356047,"about_ca_system_score_gemma":0.003581985,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001462683,"about_ca_topic_score_gemma":0.0009951605,"domain_scores_codex":[0.9956285,0.001182173,0.001709587,0.0005522681,0.0001755576,0.0007519611],"domain_scores_gemma":[0.9965268,0.0007884433,0.001550966,0.0003315389,0.0004438479,0.0003583597],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000462489,0.0001511924,0.001345382,0.01072124,0.0008608386,0.0004482865,0.0002301042,2.037399e-7,0.0004262871,0.00001721265,0.0001383547,0.9851984],"study_design_scores_gemma":[0.001733014,0.002312051,0.00003383023,0.006773852,0.001725543,0.0003642539,0.00003883094,0.000002678539,0.00006750943,0.0003167372,0.9863257,0.0003059997],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007589918,0.9855151,0.0001841305,0.01079764,0.001077949,0.001266447,0.00008162415,0.00001511073,0.0003030646],"genre_scores_gemma":[0.0001839491,0.9973048,0.001355055,0.0005000396,0.0002899886,0.0001470924,0.00001898734,0.0000643403,0.0001357384],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9861873,"threshold_uncertainty_score":0.9999074,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2164730570","doi":"10.1093/annonc/mdt009","title":"Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Etoposide; Internal medicine; Lung cancer; Oncology; Chemotherapy; Cisplatin; Chemotherapy regimen; Small Cell Lung Carcinoma; Small-cell carcinoma; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.05888404863705851,"gpt":0.4523793719581607,"spread":0.3934953233211023,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003964713,0.0002302388,0.0008649172,0.0001268091,0.0001907495,0.000005863981,0.0002914782,0.00003510754,0.000127799],"category_scores_gemma":[0.0003840832,0.0001526165,0.0001457049,0.0002377828,0.0001360298,0.0000949543,0.0002340378,0.0002498419,0.000004392742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005767108,"about_ca_system_score_gemma":0.0001733505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004638105,"about_ca_topic_score_gemma":0.0002973028,"domain_scores_codex":[0.9977834,0.0002198226,0.0006270614,0.0003834481,0.0004004046,0.0005858324],"domain_scores_gemma":[0.9973928,0.0007070065,0.0003468118,0.0005914404,0.0008358216,0.0001260635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.02188553,0.2139139,0.3640535,0.00155349,0.003665182,0.0004545767,0.0692402,0.00009365495,0.06370208,0.00007718404,0.1446129,0.1167478],"study_design_scores_gemma":[0.275746,0.3331288,0.2041928,0.0001013178,0.001078137,0.00004300121,0.08279455,0.002417644,0.06213083,0.0001144891,0.03769574,0.0005566985],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802303,0.0009257738,0.00000986996,0.009488409,0.0001467767,0.008202838,0.00002646876,0.00002407135,0.0009454321],"genre_scores_gemma":[0.996608,0.0002229074,0.0001275657,0.001043724,0.00011567,0.0008172492,0.000007247062,0.00003691467,0.001020675],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2538604,"threshold_uncertainty_score":0.6223522,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3003747453","doi":"10.1016/j.jtho.2020.01.016","title":"New Approaches to SCLC Therapy: From the Laboratory to the Clinic","year":2020,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Janssen Pharmaceuticals; National Cancer Institute; National Health and Medical Research Council; Daiichi Sankyo Europe; Agios Pharmaceuticals; Karolinska Institutet; Takeda Oncology; EMD Serono; Ipsen; PharmaMar; Astellas Pharma; Merck; Kyowa Hakko Kirin; Daiichi-Sankyo; Syndax Pharmaceuticals; Cancer Research UK; AstraZeneca; International Association for the Study of Lung Cancer; Genentech; ANGLE; Bayer Fund; Meso Scale Diagnostics; Astex Pharmaceuticals; TG Therapeutics; Aeglea BioTherapeutics; Pfizer Pharmaceuticals; Marshfield Clinic Research Foundation; Memorial Sloan-Kettering Cancer Center; Merck KGaA; National Institutes of Health; Regeneron Pharmaceuticals; Victorian Cancer Agency; Incyte; Medical Research Council; University of Texas Southwestern Medical Center; AbbVie; Celgene; Novartis; Foundation Medicine; GlaxoSmithKline; Eli Lilly and Company; Bristol-Myers Squibb; G1 Therapeutics; Lung Cancer Research Foundation; Cold Spring Harbor Laboratory; Roche; Astellas Pharma US; Amgen; Ariad Pharmaceuticals; Boehringer Ingelheim; Pfizer","keywords":"Medicine; Intensive care medicine; Lung cancer; Clinical trial; Immunotherapy; Disease; Oncology; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.3638905641609863,"gpt":0.5524615542292449,"spread":0.1885709900682587,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002655162,0.0003958338,0.003020583,0.0001777617,0.0001492516,0.00005547711,0.001294231,0.0003106945,0.0003385707],"category_scores_gemma":[0.001749608,0.0001630914,0.000768663,0.0009952128,0.0001185631,0.00005181916,0.0004402705,0.002391238,0.000613154],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009235625,"about_ca_system_score_gemma":0.00798034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003964009,"about_ca_topic_score_gemma":0.00006598319,"domain_scores_codex":[0.9956785,0.001575821,0.001195244,0.0003633481,0.0007776457,0.0004094752],"domain_scores_gemma":[0.9949343,0.002553273,0.0009526139,0.000696155,0.0002364006,0.0006272874],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000563863,0.00004928671,0.00001163057,0.0004221662,0.001297344,0.0001764148,0.0008587051,4.118187e-7,6.024265e-7,0.00000514197,0.2876888,0.7089257],"study_design_scores_gemma":[0.000305548,0.002531824,0.000104127,0.003930525,0.00167915,0.0001586083,0.0003748,2.800623e-7,0.00000258993,0.0000493122,0.9907187,0.0001445719],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000181968,0.8442825,0.0001175665,0.1519484,0.001158271,0.001551669,0.00005110143,0.00001349063,0.0008587934],"genre_scores_gemma":[0.00001153237,0.9787692,0.002818795,0.008061919,0.009065961,0.00007930039,0.000005246002,0.00006748082,0.001120534],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7087811,"threshold_uncertainty_score":0.9999103,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1481967818","doi":"10.1002/cncr.10841","title":"Twenty‐five years of clinical research for patients with limited‐stage small cell lung carcinoma in North America","year":2002,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Stage (stratigraphy); Internal medicine; Epidemiology; Radiation therapy; Surgery; Confidence interval; Survival analysis; Carcinoma; Small-cell carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.1274894484524245,"gpt":0.4271477782755311,"spread":0.2996583298231066,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000319189,0.0001189839,0.0004695937,0.0002097414,0.00004604761,0.000007795394,0.0001650096,0.00006262776,0.0001662085],"category_scores_gemma":[0.0004320503,0.00009725419,0.0000880227,0.0006477782,0.000353579,0.0000465419,0.0001119743,0.0004504785,0.00001189294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003123613,"about_ca_system_score_gemma":0.0002419957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008983489,"about_ca_topic_score_gemma":0.001127469,"domain_scores_codex":[0.9979967,0.0001110249,0.0003893799,0.0003956712,0.0005757347,0.0005314493],"domain_scores_gemma":[0.9982336,0.0005000047,0.0001143979,0.0003640038,0.0006107024,0.0001773012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0008656777,0.0004297123,0.9682996,0.0004366812,0.00007126585,0.00002577368,0.001545874,0.00003465312,0.000007743431,0.000002025602,0.01410066,0.01418037],"study_design_scores_gemma":[0.005868518,0.001654577,0.9602761,0.0001551199,0.00004298313,1.295959e-7,0.0003641642,0.000876425,0.00006238181,0.000001350417,0.03058537,0.0001128505],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993956,0.002131304,0.000006508958,0.0003476454,0.0001081708,0.001491338,0.0001481084,0.00001269953,0.00179818],"genre_scores_gemma":[0.9935759,0.001247119,0.0003071497,0.0001493343,0.0001748163,0.0003919905,0.00002267334,0.00003484312,0.004096213],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01648471,"threshold_uncertainty_score":0.3965911,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2011868684","doi":"10.1016/j.ijrobp.2004.01.055","title":"Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer","year":2004,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Etoposide; Radiation therapy; Randomization; Internal medicine; Esophagitis; Prophylactic cranial irradiation; Lung cancer; Cisplatin; Gastroenterology; Randomized controlled trial; Chemotherapy; Surgery; Urology; Conventional PCI","retraction":null,"screen_n_in":null,"score":{"opus":0.04023676340957497,"gpt":0.401698958183362,"spread":0.361462194773787,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009369629,0.0003435622,0.001194413,0.0004923071,0.0000747338,0.00003472596,0.0005561313,0.0002415285,0.0000456375],"category_scores_gemma":[0.000177787,0.0002780323,0.0002753717,0.000436589,0.0003994036,0.0003090483,0.00005590576,0.0008938618,0.000001600863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003638981,"about_ca_system_score_gemma":0.002236046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004291589,"about_ca_topic_score_gemma":0.0002561978,"domain_scores_codex":[0.9968253,0.0002833209,0.001423688,0.0004036447,0.0006208129,0.0004431676],"domain_scores_gemma":[0.9962337,0.0004980656,0.001851446,0.0002663841,0.0009529949,0.000197395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3250103,0.005738541,0.5423337,0.0001512832,0.004880851,0.0005843122,0.007863861,0.01655276,0.03990648,0.0007314964,0.0008816826,0.05536474],"study_design_scores_gemma":[0.9109098,0.01788563,0.04392885,0.001115475,0.0004121183,0.00019311,0.0002830726,0.004904295,0.0133338,0.0002179485,0.006227367,0.0005885652],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.978239,0.005399616,0.009871451,0.003692701,0.001245055,0.001050109,0.00009091994,0.00003484152,0.0003763056],"genre_scores_gemma":[0.9852831,0.007713472,0.00306317,0.0007179145,0.002877298,0.00006561392,0.00007123871,0.00005686987,0.0001512832],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5858995,"threshold_uncertainty_score":0.9999672,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2642802273","doi":"10.1016/j.jtho.2017.06.015","title":"Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":168,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Prophylactic cranial irradiation; Medicine; Oncology; Randomized controlled trial; Radiation therapy; Internal medicine; Nuclear medicine; Conventional PCI","retraction":null,"screen_n_in":null,"score":{"opus":0.05793151531993769,"gpt":0.4838327757027396,"spread":0.4259012603828019,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.003710991,0.0005155262,0.002668098,0.000706529,0.001362248,0.0001908841,0.000402384,0.0002795071,0.00006623503],"category_scores_gemma":[0.00633197,0.0004285329,0.0003672928,0.0002125227,0.000502468,0.0007042757,0.0002240626,0.0009387091,0.00000694397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002548647,"about_ca_system_score_gemma":0.003575945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003702052,"about_ca_topic_score_gemma":0.0004279298,"domain_scores_codex":[0.994627,0.001455458,0.001618874,0.0007141532,0.0008182768,0.000766253],"domain_scores_gemma":[0.9919007,0.001416779,0.002969183,0.0005164054,0.002311837,0.0008850375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.859952,0.006858086,0.008399964,0.001366218,0.001664495,0.001110802,0.01233263,0.0003678324,0.01784287,0.00002049177,0.001295248,0.08878932],"study_design_scores_gemma":[0.6848668,0.05060331,0.209979,0.0005204172,0.01297665,0.0004332298,0.002348016,0.03384876,0.0007175225,0.000422633,0.002236765,0.001046875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9720355,0.001860223,0.001967847,0.01148049,0.002265174,0.01003469,0.00005649674,0.00003825934,0.0002613672],"genre_scores_gemma":[0.9916867,0.0003536665,0.003420704,0.0004523254,0.002834677,0.0009122318,0.0000174708,0.00007533093,0.0002469173],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2015791,"threshold_uncertainty_score":0.9999378,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2981636558","doi":"10.1016/j.jtho.2019.10.013","title":"Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Charles-Le Moyne; Université de Sherbrooke; University of Alberta","funders":"Takeda Oncology; EMD Serono; National Institutes of Health; PharmaMar; Daiichi-Sankyo; G1 Therapeutics; Clovis Oncology; University of Texas Southwestern Medical Center; Merck Sharp and Dohme; Genzyme; Takeda Pharmaceuticals U.S.A.; Foundation Medicine; United Therapeutics Corporation; F. Hoffmann-La Roche; Ipsen Biopharmaceuticals; Novartis; Celgene; Merck; Spectrum Pharmaceuticals; Purdue University; MedImmune; Sanofi; GlaxoSmithKline; Roche; AbbVie; Genentech; Aeglea BioTherapeutics; Amgen; Daiichi Sankyo Europe; National Cancer Institute; Intuitive Surgical; Moderna; Pfizer; AstraZeneca; Purdue Pharma; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Paclitaxel; Hazard ratio; Internal medicine; Oncology; Placebo; Clinical endpoint; Population; Gastroenterology; Confidence interval; Randomized controlled trial; Chemotherapy; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1253425639402656,"gpt":0.5412142173577857,"spread":0.4158716534175201,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003841329,0.0003317407,0.002970163,0.0005660837,0.0001700839,0.00001786989,0.0002227827,0.0002006233,0.000323972],"category_scores_gemma":[0.001961002,0.0002158946,0.0004751708,0.0003289203,0.0005048514,0.0002489254,0.0001812545,0.0005559537,0.000004472546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008884407,"about_ca_system_score_gemma":0.001509733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007480133,"about_ca_topic_score_gemma":0.00005304083,"domain_scores_codex":[0.9960935,0.001083913,0.001347839,0.000358822,0.0006875956,0.0004283924],"domain_scores_gemma":[0.9918698,0.004976104,0.001444494,0.0003452272,0.001084769,0.0002795789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9454451,0.002561261,0.0003535889,0.0003066671,0.007499869,0.0001587589,0.006320353,0.00003140644,0.007330481,0.00001521511,0.002481973,0.02749536],"study_design_scores_gemma":[0.8778419,0.09849394,0.001675581,0.0002832824,0.002517707,0.0002117804,0.01239341,0.001101416,0.001538014,0.0002164456,0.003465723,0.0002607692],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980163,0.009803067,0.000197781,0.002209798,0.001006075,0.00413379,0.00004482106,0.00001436981,0.002427277],"genre_scores_gemma":[0.9945428,0.001300084,0.000888397,0.0003230718,0.000256507,0.0001166232,0.00001392191,0.00003985228,0.002518788],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09593268,"threshold_uncertainty_score":0.8803927,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2076643424","doi":"10.1016/s0360-3016(02)04576-5","title":"Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? a community-based population analysis","year":2003,"lang":"en","type":"review","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Victoria; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Comorbidity; Internal medicine; Population; Chemoradiotherapy; Lung cancer; Multivariate analysis; Cancer; Radiation therapy; Retrospective cohort study; Stage (stratigraphy); Cancer registry; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.09335179534133689,"gpt":0.4679631660074854,"spread":0.3746113706661486,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00104942,0.0004323442,0.002276206,0.0009705498,0.0001204284,0.00005938867,0.000243055,0.0003616604,0.00002286573],"category_scores_gemma":[0.0002583528,0.000318405,0.0005756792,0.000560184,0.0001669476,0.000142409,0.00007249854,0.0009435713,9.533412e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00515762,"about_ca_system_score_gemma":0.001163457,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001976344,"about_ca_topic_score_gemma":0.0006299914,"domain_scores_codex":[0.9965587,0.001471178,0.001098777,0.0002980604,0.0003070454,0.0002662013],"domain_scores_gemma":[0.9961466,0.001251058,0.001693335,0.0002582436,0.0004787856,0.0001720387],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001471619,0.0006994103,0.6436006,0.0007410226,0.006181825,0.00006753019,0.0003701459,0.0004962792,0.000007272101,0.0001013694,0.00005039886,0.347537],"study_design_scores_gemma":[0.03108793,0.00683383,0.64675,0.005178966,0.02848356,0.0001721155,0.0003079908,0.007338076,0.00002636704,0.0007580174,0.2715214,0.001541741],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.1951617,0.800897,0.0008312052,0.0005746929,0.0005299988,0.001330304,0.0005506623,0.00002684305,0.00009758909],"genre_scores_gemma":[0.1014935,0.8963376,0.0005366385,0.0001697719,0.0002606645,0.0000895138,0.001015084,0.0000359166,0.0000613001],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3459953,"threshold_uncertainty_score":0.9999268,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2112870137","doi":"10.1200/jco.2005.03.171","title":"Influence of Sex on Toxicity and Treatment Outcome in Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre; Cancer Care Ontario; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Toxicity; Leukopenia; Gastroenterology; Vomiting; Vincristine; Etoposide; Chemotherapy; Stomatitis; Cyclophosphamide; Lung cancer; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.1698502529833859,"gpt":0.5546774789976718,"spread":0.384827226014286,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00152005,0.00009778066,0.001202962,0.0001170508,0.00001561567,0.000002113451,0.00008236818,0.0001502983,0.00003011466],"category_scores_gemma":[0.001437487,0.00006044688,0.0001552352,0.00008541668,0.0001814798,0.00004741668,0.00004715859,0.0005542374,0.000001863977],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006442981,"about_ca_system_score_gemma":0.0009463385,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001784846,"about_ca_topic_score_gemma":0.0008234879,"domain_scores_codex":[0.997771,0.0002037735,0.001486713,0.0001333764,0.0002172108,0.00018796],"domain_scores_gemma":[0.9971185,0.001713624,0.0006576579,0.0001152768,0.0001845848,0.0002103683],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002001063,0.001841892,0.9231246,0.00005981575,0.0001899441,0.0001731962,0.0003023535,0.0006866275,0.000336898,0.00001012449,0.0003112462,0.07096223],"study_design_scores_gemma":[0.01206121,0.01386709,0.9616976,0.0001648297,0.0001629355,0.00002724144,0.00007441679,0.0001723589,0.001110602,0.00001958422,0.01058468,0.00005748581],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843718,0.001455641,0.000001952924,0.01245038,0.00009459187,0.0002087274,0.000002680243,0.000002484884,0.001411721],"genre_scores_gemma":[0.9911696,0.005768641,0.0005537426,0.001580929,0.0004461383,0.000007338175,1.05389e-7,0.000006507851,0.0004670178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07090475,"threshold_uncertainty_score":0.2464952,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2564674425","doi":"10.1016/j.jtho.2016.12.004","title":"The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; H&E stain; Pathology; Immunohistochemistry; Biopsy; Lung cancer; Differential diagnosis; Carcinoma; Medical diagnosis; Radiology","retraction":null,"screen_n_in":null,"score":{"opus":0.09684801767149295,"gpt":0.481293159134783,"spread":0.38444514146329,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001908924,0.000110194,0.0005552282,0.0001038793,0.00005689489,0.00000810251,0.0002777609,0.00005985448,0.00002628179],"category_scores_gemma":[0.004391328,0.00005086175,0.00009789054,0.0001081266,0.0003078525,0.0001321356,0.000234759,0.0002538178,3.730507e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000397531,"about_ca_system_score_gemma":0.000339189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004001284,"about_ca_topic_score_gemma":0.0004712546,"domain_scores_codex":[0.998108,0.0003437148,0.0007992812,0.0002485564,0.0003354345,0.0001650581],"domain_scores_gemma":[0.9953924,0.002599376,0.0009273829,0.000434896,0.0005872279,0.00005869248],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003217495,0.0009689347,0.8963239,0.0003082532,0.000480867,0.00006023304,0.002103586,0.000005526054,0.0691025,0.00000223983,0.0002381252,0.02718835],"study_design_scores_gemma":[0.002035347,0.002937055,0.8480885,0.000720544,0.000549589,0.00008977191,0.001742395,0.00006414278,0.1433513,0.00002555023,0.000316481,0.0000793396],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916368,0.004570368,0.000005034473,0.002946917,0.0002773672,0.0005099052,0.00003958252,0.000001816818,0.00001221108],"genre_scores_gemma":[0.9934227,0.006156906,0.00006042261,0.00001401337,0.0001735602,0.00009743024,4.646349e-7,0.000008617818,0.00006586331],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07424881,"threshold_uncertainty_score":0.5257146,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2611025812","doi":"10.1016/j.lungcan.2017.04.021","title":"Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival","year":2017,"lang":"en","type":"article","venue":"Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Propensity score matching; Radiation therapy; Chemotherapy; Lung cancer; Oncology; Surgery; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03873701686102035,"gpt":0.3714446377825013,"spread":0.332707620921481,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004310796,0.0002755579,0.001328852,0.0002206999,0.0002855736,0.00007824015,0.0001717047,0.0001026287,0.00006267977],"category_scores_gemma":[0.0001216136,0.0002294307,0.000217235,0.0002497286,0.000341837,0.0001511647,0.00008375029,0.0001675614,9.880483e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003431333,"about_ca_system_score_gemma":0.0004543796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004323998,"about_ca_topic_score_gemma":0.003564793,"domain_scores_codex":[0.9982465,0.0000454624,0.0003278307,0.0005507239,0.0003534434,0.0004760783],"domain_scores_gemma":[0.9981231,0.0003742303,0.0003314937,0.0005977793,0.000375906,0.000197456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009662268,0.00008443223,0.9354464,0.001822862,0.007933772,0.0000121237,0.001679378,0.00006405559,0.01180039,0.00001683448,0.001081503,0.03039602],"study_design_scores_gemma":[0.01495453,0.0004548814,0.9589415,0.0006043954,0.003944175,0.000001096592,0.0001272888,0.009382363,0.007465178,0.000007514525,0.003623781,0.000493254],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9620175,0.03261461,0.0004574655,0.002562385,0.0003986331,0.001554638,0.0001206262,0.00003519883,0.0002389277],"genre_scores_gemma":[0.9559302,0.04061136,0.0008853292,0.0002390491,0.0002753656,0.0005899028,0.00001227208,0.00006948604,0.001387057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02990277,"threshold_uncertainty_score":0.9355912,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2062668422","doi":"10.1002/1097-0142(20001101)89:9<1953::aid-cncr11>3.3.co;2-y","title":"Similar outcome of elderly patients in Intergroup Trial 0096","year":2000,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"","keywords":"Medicine; Toxicity; Internal medicine; Etoposide; Retrospective cohort study; Survival rate; Performance status; Radiation therapy; Surgery; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03867075491290355,"gpt":0.4024898100377814,"spread":0.3638190551248778,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001037434,0.00008988407,0.0003152248,0.00007870916,0.00001520912,0.000003546481,0.00008162457,0.00004288073,0.00198942],"category_scores_gemma":[0.000101941,0.00007018428,0.00006907422,0.0001763874,0.00007487542,0.00004960617,0.00002807994,0.0001540422,0.00002536108],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002613391,"about_ca_system_score_gemma":0.00007475894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006227563,"about_ca_topic_score_gemma":0.0004165257,"domain_scores_codex":[0.9990153,0.00002642616,0.0002882905,0.0001656604,0.0002878413,0.0002165245],"domain_scores_gemma":[0.9996023,0.00003527652,0.00003862906,0.0001848081,0.00007609,0.00006287882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01962686,0.0003276239,0.8372352,0.0002089048,0.0001063009,0.00001574683,0.0007633538,0.00001151536,0.00008363472,0.00001066217,0.009528922,0.1320813],"study_design_scores_gemma":[0.1322548,0.003570401,0.7818822,0.0006110037,0.0000937524,7.663572e-7,0.0001257389,0.00004961322,0.001150999,0.0001087761,0.07989442,0.000257565],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917499,0.0006466538,0.000001116311,0.0007574685,0.0002431088,0.0005876172,0.00001945697,0.00001465564,0.005979985],"genre_scores_gemma":[0.9956285,0.0005526107,0.00002796726,0.0003031694,0.0001742691,0.0001242224,0.000005287553,0.00001330434,0.003170646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1318237,"threshold_uncertainty_score":0.9989229,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2212041110","doi":"10.1016/s1556-0864(15)31579-3","title":"A Review of First-Line Treatment for Small-cell Lung Cancer","year":2006,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Etoposide; Prophylactic cranial irradiation; Radiation therapy; Chemotherapy; Oncology; Regimen; Lung cancer; Cisplatin; Clinical trial; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1395104637584422,"gpt":0.5695194519831677,"spread":0.4300089882247255,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001221893,0.0004388466,0.006084387,0.0003898518,0.00005872221,0.000005508433,0.0002940028,0.0003233671,0.0001316669],"category_scores_gemma":[0.0004078037,0.0002591662,0.001854806,0.0003476365,0.0001129022,0.00003509035,0.000084108,0.0005550744,0.000002980851],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003819098,"about_ca_system_score_gemma":0.004654768,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008433912,"about_ca_topic_score_gemma":0.000170232,"domain_scores_codex":[0.9966555,0.00029934,0.001999547,0.0002722934,0.0003547617,0.0004186223],"domain_scores_gemma":[0.9944327,0.0009589219,0.002984096,0.0003599752,0.001064104,0.0002001446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000218742,0.0004338893,0.00001829744,0.3682663,0.001219815,0.0001240985,0.00001830117,7.462153e-7,3.796716e-7,7.662206e-7,0.04785059,0.5818481],"study_design_scores_gemma":[0.0008607547,0.003834372,0.000001972191,0.2339898,0.01612271,0.0004327848,0.000005293032,0.000003163156,0.000008310053,0.00000549399,0.7446111,0.0001242196],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00000604434,0.9923308,0.00009200376,0.002516139,0.0006305723,0.003136382,0.0001544122,0.000007521939,0.001126121],"genre_scores_gemma":[9.797693e-7,0.9921924,0.002097689,0.0002443161,0.001661916,0.0005331779,0.00003649479,0.00006427842,0.003168784],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6967606,"threshold_uncertainty_score":0.9999861,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149519864","doi":"10.1002/cncr.22235","title":"Extrapulmonary small cell cancer","year":2006,"lang":"en","type":"article","venue":"Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Saskatchewan Cancer Agency; University of Alberta; University of Saskatchewan","funders":"","keywords":"Medicine; Confidence interval; Internal medicine; Odds ratio; Genitourinary system; Gastroenterology; Carcinoma; Cancer; Medical record; Survival analysis; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.03055779452167537,"gpt":0.3429949897304098,"spread":0.3124371952087345,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006887932,0.0001498137,0.0002398119,0.00006979395,0.00008595734,0.00001304481,0.00009657728,0.00005847056,0.001383196],"category_scores_gemma":[0.000009365412,0.0001210111,0.00008745655,0.0002129972,0.0001141271,0.00004405887,0.00005803146,0.000203227,0.00006414887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004375989,"about_ca_system_score_gemma":0.0003699152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005100168,"about_ca_topic_score_gemma":0.00100495,"domain_scores_codex":[0.9988329,0.00001642835,0.0001605763,0.0002949149,0.0002792341,0.0004159897],"domain_scores_gemma":[0.9994264,0.00003036471,0.00004263756,0.0002477699,0.0001393781,0.0001134729],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000402654,0.0002966279,0.4663519,0.0009450552,0.0001708252,0.0003318307,0.0002734426,0.0001899159,0.05613197,0.0002113335,0.4392009,0.03549356],"study_design_scores_gemma":[0.002222467,0.0001411974,0.317052,0.000327412,0.0001786084,0.00001352915,0.0001000497,0.0001436085,0.03817339,0.0002810184,0.6410238,0.0003429339],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7515475,0.1096072,0.00006693589,0.007405991,0.0007470562,0.0007699526,0.00008535122,0.0001973288,0.1295727],"genre_scores_gemma":[0.9237071,0.00455986,0.0002344996,0.001024682,0.001785164,0.0006372317,0.00001265677,0.00004655208,0.06799227],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2018229,"threshold_uncertainty_score":0.9995297,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2101599998","doi":"10.1158/1535-7163.mct-09-0243","title":"Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations <i>in vitro</i> and <i>in vivo</i>","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Irinotecan; Cisplatin; In vivo; Pharmacology; Drug; In vitro; Cytotoxicity; Chemistry; Medicine; Liposome; Chemotherapy; Cancer; Biology; Internal medicine; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01875205029635636,"gpt":0.3266822291234521,"spread":0.3079301788270958,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001953414,0.0001508376,0.0003472312,0.0001589541,0.00004149247,0.0000162614,0.00006293927,0.00004682623,0.000006813242],"category_scores_gemma":[0.00001477325,0.0001425803,0.00003393763,0.0002658544,0.0001346956,0.00006603387,0.00004397821,0.0002362592,2.255074e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001524716,"about_ca_system_score_gemma":0.0001293024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000354561,"about_ca_topic_score_gemma":0.000357149,"domain_scores_codex":[0.9988867,0.00007280699,0.0002062114,0.0002615352,0.0003199568,0.0002528097],"domain_scores_gemma":[0.999543,0.00004675838,0.0000680457,0.0002043219,0.00007173561,0.00006616513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004387306,0.0003398665,0.007252231,0.000110475,0.00006645879,0.0000689388,0.0005856142,0.00003868677,0.9716805,0.0002237907,0.00002270883,0.01917202],"study_design_scores_gemma":[0.004234185,0.0002433711,0.0535774,0.000160619,0.00008138512,0.00001198637,0.00008760495,0.001316682,0.9391633,0.0004316868,0.0005179433,0.0001738143],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858716,0.006388355,0.0002443351,0.006201064,0.00003608386,0.000560583,0.00002769592,0.00001497423,0.0006553064],"genre_scores_gemma":[0.9962676,0.002270774,0.0001750387,0.001094319,0.0000132136,0.00003572761,0.000001879072,0.00001467332,0.0001268004],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04632517,"threshold_uncertainty_score":0.5814254,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4220915836","doi":"10.1016/j.ijrobp.2022.03.020","title":"Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors","year":2022,"lang":"en","type":"article","venue":"International Journal of Radiation Oncology*Biology*Physics","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; National Institutes of Health; National Center for Advancing Translational Sciences; University of Minnesota","keywords":"Medicine; Lung cancer; Internal medicine; Adenocarcinoma; Oncology; Anaplastic lymphoma kinase; Brain metastasis; Lung; Epidermal growth factor receptor; Cancer; Population; Metastasis","retraction":null,"screen_n_in":null,"score":{"opus":0.02320506572987794,"gpt":0.3732619163356526,"spread":0.3500568506057747,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001036817,0.0002502109,0.0006346543,0.0001098893,0.0002414376,0.00002176651,0.0003255342,0.00007667772,0.000009349596],"category_scores_gemma":[0.0004161192,0.0001309778,0.0001488979,0.0002207963,0.0004160699,0.00009306971,0.0003335169,0.0004981133,6.453966e-9],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006565254,"about_ca_system_score_gemma":0.001169798,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004734306,"about_ca_topic_score_gemma":0.0001471945,"domain_scores_codex":[0.9977586,0.0004560641,0.0007080615,0.000283319,0.0005244138,0.0002695758],"domain_scores_gemma":[0.9955432,0.001562843,0.001959174,0.0001648095,0.0006905168,0.00007949048],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0007019104,0.0002566753,0.9905993,0.0004329145,0.001597192,0.000006458278,0.001430391,0.0005440446,0.001458162,0.00005722087,0.0002509656,0.002664754],"study_design_scores_gemma":[0.01600754,0.003784769,0.951289,0.0007149526,0.003072003,0.0000549195,0.000391222,0.004826349,0.01799244,0.0001561564,0.001439928,0.0002706889],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910586,0.002251925,0.0003350185,0.001950312,0.0006242787,0.003012019,0.0007430859,0.000005944718,0.00001881435],"genre_scores_gemma":[0.9981769,0.0003804573,0.0002795006,0.0002265884,0.0002408645,0.0006075348,0.00003700376,0.00003328119,0.00001790079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03931029,"threshold_uncertainty_score":0.5341118,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4306247391","doi":"10.1016/s2213-2600(22)00309-5","title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial","year":2022,"lang":"en","type":"article","venue":"The Lancet Respiratory Medicine","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Jazz Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; GlaxoSmithKline; Servier; Amgen; Pfizer; PharmaMar; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Clinical endpoint; Chemotherapy; Population; Febrile neutropenia; Oncology; Doxorubicin; Topotecan; Vincristine; Anthracycline; Clinical trial; Surgery; Cyclophosphamide; Cancer; Neutropenia; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0657955502563836,"gpt":0.3892918764154446,"spread":0.323496326159061,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001246748,0.0002599088,0.001061804,0.0001865267,0.0002059974,0.00001323214,0.0004022027,0.00004347189,0.0001277982],"category_scores_gemma":[0.0003771536,0.0001600351,0.00002832191,0.0007252877,0.0003029393,0.00009852791,0.000231803,0.0005911167,5.115501e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003616209,"about_ca_system_score_gemma":0.0002522663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009420719,"about_ca_topic_score_gemma":0.0002292334,"domain_scores_codex":[0.9973686,0.0004492195,0.0004928445,0.0004066947,0.0008541009,0.0004285116],"domain_scores_gemma":[0.998098,0.0006984684,0.0003819512,0.0004938365,0.0002180823,0.0001096678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.929752,0.003010796,0.03931009,0.0004614395,0.0004844434,0.00002714141,0.002229447,0.00002131819,0.005644782,0.00004953119,0.01452034,0.004488662],"study_design_scores_gemma":[0.9544728,0.01099527,0.02518866,0.0004006765,0.0003233149,3.924453e-7,0.000345977,0.0004311722,0.0008256343,0.000005025798,0.006835998,0.0001750778],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985546,0.003452217,0.000003527832,0.003316657,0.0004280298,0.005930043,0.00003719618,0.00003160142,0.001254749],"genre_scores_gemma":[0.9955657,0.0004398198,0.00002644296,0.002102522,0.0006036481,0.0009386576,0.00004652032,0.00004639359,0.0002302727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02472079,"threshold_uncertainty_score":0.652604,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2124177114","doi":"","title":"Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Protein kinase B; MAPK/ERK pathway; Kinase; Cancer research; Protein kinase A; Biology; Medicine; Internal medicine; Pathology; Signal transduction; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01654411216181807,"gpt":0.245202566691321,"spread":0.2286584545295029,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002467268,0.0002150123,0.0003698897,0.00014097,0.00006087501,0.00001709753,0.00006232282,0.00006631103,0.000007860132],"category_scores_gemma":[0.0004943862,0.0001582596,0.00001916891,0.000339565,0.0001905052,0.0001007594,0.00006316249,0.0002270081,1.672199e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001746039,"about_ca_system_score_gemma":0.0001555477,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003433107,"about_ca_topic_score_gemma":0.00007018683,"domain_scores_codex":[0.9982846,0.0001375322,0.000255723,0.0004396158,0.000375701,0.0005068079],"domain_scores_gemma":[0.9991509,0.00005555619,0.000143412,0.000226877,0.0001857006,0.0002375877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001922663,0.0005068416,0.8711579,0.00250893,0.00005897685,0.00003420746,0.0004532394,0.000002627145,0.115294,0.000006512976,0.00006839998,0.007985651],"study_design_scores_gemma":[0.005094345,0.0002485542,0.5778942,0.0006310419,0.00003508337,5.017392e-7,0.00005821002,0.000005018307,0.4157225,0.000008358154,0.000159085,0.0001431403],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858357,0.002520504,0.00001207658,0.0001252294,0.00002573615,0.01120343,0.00002261199,0.00002616723,0.0002285475],"genre_scores_gemma":[0.9856333,0.00004822358,0.0005231513,0.00001746504,0.0000178386,0.01322069,0.000005838909,0.00003214136,0.0005013951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3004285,"threshold_uncertainty_score":0.6453638,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2505623435","doi":"10.1093/annonc/mdw263","title":"Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; BC Cancer Agency","funders":"Institut Gustave-Roussy; National Cancer Institute; Ligue Contre le Cancer; Sanofi; Eli Lilly and Company","keywords":"Medicine; Radiation therapy; Hazard ratio; Lung cancer; Randomized controlled trial; Meta-analysis; Stage (stratigraphy); Log-rank test; Clinical trial; Survival analysis; Surgery; Internal medicine; Oncology; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.5676325483529087,"gpt":0.5740618394205091,"spread":0.006429291067600484,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002019379,0.000458893,0.007466447,0.0009858978,0.00003209483,0.000005841755,0.001367309,0.0003569593,0.0004217571],"category_scores_gemma":[0.0004393664,0.0002199982,0.00291835,0.001696996,0.0004085152,0.00007945398,0.0008849289,0.000543527,6.296576e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003465012,"about_ca_system_score_gemma":0.003201362,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001682154,"about_ca_topic_score_gemma":0.0006409544,"domain_scores_codex":[0.9951534,0.001385449,0.001616374,0.000614095,0.0007123475,0.0005183418],"domain_scores_gemma":[0.9935114,0.001509742,0.002348532,0.002033302,0.0004837049,0.0001133548],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002031339,0.0006690929,0.003943936,0.01649175,0.3118461,0.00002783426,0.00068613,0.00004444741,0.000008475054,0.000003691001,0.003396588,0.6626788],"study_design_scores_gemma":[0.001062865,0.002909852,0.002051816,0.005251379,0.4021497,0.00001138401,0.00009878568,0.00005368812,0.0002213954,0.000004109353,0.585726,0.0004590742],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003995203,0.989705,0.00001538773,0.0004967473,0.00007609683,0.001722528,0.003749545,0.000009256634,0.0002302951],"genre_scores_gemma":[0.003452957,0.9956306,0.0001246355,0.00009206359,0.00006494884,0.0002443632,0.0001258223,0.0000618308,0.0002027803],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6622197,"threshold_uncertainty_score":0.8971266,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391219445","doi":"10.1016/j.ccell.2024.01.001","title":"Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes","year":2024,"lang":"en","type":"article","venue":"Cancer Cell","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Horizon 2020; Daiichi Sankyo Europe; National Cancer Institute; HORIZON EUROPE Framework Programme; University of Texas MD Anderson Cancer Center; EMD Serono; Foundation Medicine; Sierra Oncology; Sociedad Española de Oncología Médica; Birla Institute of Scientific Research; PharmaMar; European Society for Medical Oncology; Rexanna's Foundation; BeiGene; Mirati Therapeutics; Pfizer; Innovent Biologics; Medical Research Council; Les Laboratories Pierre Fabre; Jazz Pharmaceuticals; Francis Crick Institute; National Institutes of Health; Regeneron Pharmaceuticals; Cancer Moonshot; Albert Einstein Cancer Center; Genentech; Cancer Prevention and Research Institute of Texas; Moonshot Research and Development Program; Sanofi; GlaxoSmithKline; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Wellcome Trust; Cancer Research UK; Spectrum Pharmaceuticals; Amgen; Agence Nationale de la Recherche; LUNGevity Foundation","keywords":"Subtyping; DNA methylation; Epigenetics; Biology; Lung cancer; Malignancy; Cancer research; Methylation; Oncology; Gene; Medicine; Gene expression; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.03025156051891841,"gpt":0.3632239743680075,"spread":0.332972413849089,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005379523,0.0002615315,0.0004464069,0.0001107798,0.000145794,0.0001291491,0.0001842477,0.00009826553,0.0004892531],"category_scores_gemma":[0.0002136274,0.0002172446,0.0001393716,0.0002910019,0.0001834239,0.0001727042,0.0002513706,0.0004337728,0.00002313461],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006011117,"about_ca_system_score_gemma":0.0006732566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001889682,"about_ca_topic_score_gemma":0.001160814,"domain_scores_codex":[0.9978035,0.00007599028,0.0004960221,0.0006870245,0.0004648773,0.0004725608],"domain_scores_gemma":[0.9985797,0.0003760216,0.0001118982,0.0004856085,0.0002302285,0.0002165833],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001179428,0.0003608102,0.2802992,0.03825891,0.00188342,0.001146177,0.01408254,0.0003636871,0.4308437,0.0003926856,0.1793413,0.05184808],"study_design_scores_gemma":[0.0158042,0.001906154,0.2842867,0.01342522,0.007141408,0.0001192291,0.004508305,0.04001543,0.4507287,0.004791946,0.1735122,0.003760437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7636243,0.2218747,0.0001514382,0.002579726,0.001291161,0.0008282099,0.00008299314,0.0002275383,0.009339925],"genre_scores_gemma":[0.965683,0.0221704,0.0003620979,0.0004515049,0.0009616243,0.0003136913,0.00001461236,0.00008087103,0.009962135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2020588,"threshold_uncertainty_score":0.8858979,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2464196345","doi":"10.1016/s1470-2045(16)30065-1","title":"Prophylactic cranial irradiation for patients with lung cancer","year":2016,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Neurocognitive; Brain metastasis; Lung cancer; Incidence (geometry); Oncology; Quality of life (healthcare); Internal medicine; Cancer; Lung; Radiation therapy; Surgery; Metastasis","retraction":null,"screen_n_in":null,"score":{"opus":0.08109539761877588,"gpt":0.4781793741447576,"spread":0.3970839765259818,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003859507,0.0002642219,0.001879042,0.00008016694,0.0001324609,0.00001125863,0.000241436,0.000188488,0.00009093814],"category_scores_gemma":[0.0002784999,0.0001066939,0.0001585922,0.0001543406,0.0001825128,0.00003947913,0.00007301673,0.000367112,0.00002950776],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001640788,"about_ca_system_score_gemma":0.001671574,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003062947,"about_ca_topic_score_gemma":0.00005663801,"domain_scores_codex":[0.9983764,0.0002226839,0.0002848549,0.0003277042,0.0002870914,0.000501294],"domain_scores_gemma":[0.9982368,0.0006761601,0.0003397326,0.0004192123,0.0002555424,0.0000725365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001052924,0.00009693787,0.0005851593,0.02832675,0.0007298019,0.000006541716,0.00009437837,8.345734e-8,1.469355e-7,0.00009282713,0.01615442,0.9528601],"study_design_scores_gemma":[0.003787924,0.001334784,0.000831831,0.004143308,0.001768764,0.000008150284,0.000002417532,0.000002502144,7.713381e-8,0.00002700716,0.9879487,0.000144533],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000320882,0.98865,0.00003206329,0.003422365,0.0005487899,0.005644144,0.0002284414,0.00004638428,0.001395727],"genre_scores_gemma":[0.0001116317,0.990256,0.0001497633,0.0002966551,0.003598549,0.004272269,0.00006562179,0.0000610719,0.00118842],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9717943,"threshold_uncertainty_score":0.4350851,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2035885090","doi":"10.1093/annonc/mdv104","title":"Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chemoradiotherapy; Internal medicine; Placebo; Clinical endpoint; Oncology; Subgroup analysis; Biomarker; Lung cancer; Surrogate endpoint; Stage (stratigraphy); Phases of clinical research; Cancer; Gastroenterology; Clinical trial; Pathology; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.2260875689088964,"gpt":0.5120381683515557,"spread":0.2859505994426593,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002456047,0.000201389,0.0008348438,0.0003950398,0.0000553901,0.00001545255,0.0002244677,0.00009514311,0.0001161327],"category_scores_gemma":[0.0002308904,0.0001374415,0.00005356273,0.0006822832,0.0002285744,0.0001121495,0.0002313483,0.0003513317,0.000001674784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002036456,"about_ca_system_score_gemma":0.0008717983,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.030897,"about_ca_topic_score_gemma":0.03071141,"domain_scores_codex":[0.9975846,0.0005257555,0.0005161227,0.0003683707,0.0004534634,0.0005517207],"domain_scores_gemma":[0.9986161,0.0003513278,0.0001615466,0.0003565802,0.0003576907,0.0001567597],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01586887,0.008767365,0.8534012,0.0004144441,0.001452942,0.001819356,0.01867753,0.0002984756,0.01696622,0.00003170039,0.07443731,0.007864619],"study_design_scores_gemma":[0.159232,0.02009031,0.7156545,0.00038016,0.0005853918,0.00002209616,0.05947377,0.005803282,0.009031785,0.0001304982,0.02885091,0.0007453162],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816443,0.003342788,0.000009330102,0.004498216,0.0001124999,0.001431176,0.00004462785,0.00001230552,0.008904734],"genre_scores_gemma":[0.9970121,0.001217243,0.0000286484,0.0005346722,0.00005687463,0.0001433681,0.00001930046,0.00001777845,0.0009700112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1433631,"threshold_uncertainty_score":0.9869756,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3047400464","doi":"10.1016/j.annonc.2020.07.001","title":"The FDA approval of pembrolizumab for patients with TMB &gt;10 mut/Mb: was it a wise decision? No","year":2020,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Arnold Ventures; Roche; Takeda Pharmaceuticals U.S.A.; Pfizer","keywords":"Medicine; Pembrolizumab; Crizotinib; Nivolumab; Ipilimumab; Oncology; Family medicine; Internal medicine; Lung cancer; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.07303249655138225,"gpt":0.4114210955109136,"spread":0.3383885989595313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000386605,0.000353161,0.001432811,0.0001632685,0.0001347727,0.00001071493,0.0005407305,0.0004525637,0.0001299143],"category_scores_gemma":[0.002678256,0.0002045021,0.0003417383,0.0002313556,0.0008168601,0.0000465985,0.0002969157,0.00097942,0.00004660973],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001357715,"about_ca_system_score_gemma":0.00125558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004664551,"about_ca_topic_score_gemma":0.00004483418,"domain_scores_codex":[0.9968442,0.0001621434,0.0007262132,0.0005306717,0.001052501,0.0006843273],"domain_scores_gemma":[0.9933837,0.002688852,0.0006189229,0.0006603695,0.002516738,0.0001313967],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01152317,0.0002696763,0.0004555903,0.0009298414,0.001127974,0.00017524,0.000246516,7.60335e-7,0.000009645928,0.00001259323,0.9648827,0.02036633],"study_design_scores_gemma":[0.006013174,0.02134203,0.0009016781,0.0003672861,0.0002648929,0.000009785106,0.00004885038,0.00001477725,0.00006669456,0.0002808584,0.9705162,0.0001737597],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.007659433,0.00121505,0.00004223272,0.9775727,0.0005272388,0.003271024,0.0004804257,0.00002903545,0.009202817],"genre_scores_gemma":[0.02484317,0.004616013,0.00482762,0.9345333,0.007604616,0.002058142,0.001137938,0.000354603,0.02002459],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.04303944,"threshold_uncertainty_score":0.8339356,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3084355783","doi":"10.1016/j.jtho.2020.08.022","title":"Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC","year":2020,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Genentech; National Institutes of Health; Innovent Biologics; Jounce Therapeutics; Jazz Pharmaceuticals; Varian Medical Systems; Sierra Oncology; F. Hoffmann-La Roche; Novartis; National Cancer Institute; Johnson and Johnson; AbbVie; MedImmune; Merck; GlaxoSmithKline; Spectrum Pharmaceuticals; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Medicine; Pembrolizumab; Common Terminology Criteria for Adverse Events; Internal medicine; Neutropenia; Oncology; Pneumonitis; Chemoradiotherapy; Radiation therapy; Progression-free survival; Surgery; Chemotherapy; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1139402507692928,"gpt":0.5265962188109286,"spread":0.4126559680416357,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005838394,0.00009520361,0.0006536226,0.00009027251,0.00003625074,0.000007402107,0.00008131428,0.00007909102,0.00003714982],"category_scores_gemma":[0.0009228496,0.00006887132,0.0001419815,0.000126246,0.0001237101,0.00007929547,0.00002903603,0.0002499054,7.330869e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001646828,"about_ca_system_score_gemma":0.0006056464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000001870713,"about_ca_topic_score_gemma":9.592416e-7,"domain_scores_codex":[0.9988438,0.0001085215,0.0005011724,0.0001146488,0.00027228,0.0001595303],"domain_scores_gemma":[0.9984228,0.0003347604,0.0005563417,0.00007399906,0.0004215228,0.0001906044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3528638,0.001258758,0.000177959,0.0004156317,0.0004433593,0.00006048534,0.001338804,0.000003998628,0.01601483,0.0000487272,0.01024165,0.6171319],"study_design_scores_gemma":[0.4222257,0.1519222,0.0009466354,0.0001636293,0.0005374862,0.0001686921,0.0008609237,0.001740482,0.02986998,0.0001018996,0.3912966,0.000165772],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9682306,0.004062353,0.0007523131,0.02516142,0.000458896,0.0009525289,0.00002753132,0.000007842872,0.0003465114],"genre_scores_gemma":[0.994319,0.002708989,0.0009307812,0.0007291759,0.001185123,0.00001940633,0.000004558495,0.00001297725,0.00009003929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6169662,"threshold_uncertainty_score":0.2808491,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2189143821","doi":"10.1016/j.cllc.2015.09.007","title":"Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis","year":2015,"lang":"en","type":"review","venue":"Clinical Lung Cancer","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Radiation therapy; Stage (stratigraphy); Lung cancer; Meta-analysis; Oncology; Radiology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.4089820723585534,"gpt":0.6118290681439336,"spread":0.2028469957853802,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.003928778,0.001373339,0.01681764,0.0006601655,0.0002249075,0.0001127855,0.0009109352,0.001007424,0.002215087],"category_scores_gemma":[0.001004806,0.0008971493,0.01379709,0.001969804,0.0005109768,0.0001041426,0.0003346941,0.00198743,0.00001972608],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003007435,"about_ca_system_score_gemma":0.007213742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006285594,"about_ca_topic_score_gemma":0.0006336087,"domain_scores_codex":[0.9909355,0.001097238,0.002950151,0.002358385,0.001280793,0.001377927],"domain_scores_gemma":[0.9896223,0.003261271,0.001741611,0.00214643,0.002132885,0.001095485],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004968272,0.0002726034,0.0006165982,0.05531236,0.5352566,0.00009063247,0.0001095377,0.00003472038,2.073603e-7,0.00001184204,0.1282303,0.2795677],"study_design_scores_gemma":[0.0009835765,0.0002265556,0.00001037736,0.001271644,0.4431104,0.000002366568,0.00001467126,0.0003903155,5.944228e-7,0.000003555798,0.5534877,0.0004982825],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000006613453,0.9819186,0.0007987004,0.001476558,0.001175861,0.01055252,0.003345804,0.0001625974,0.0005627226],"genre_scores_gemma":[0.000002066535,0.929442,0.001697604,0.001596824,0.003013561,0.01487654,0.0003139734,0.0003156906,0.04874178],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4252573,"threshold_uncertainty_score":0.9999017,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2129527916","doi":"10.1097/01.jto.0000263720.15062.51","title":"Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline","year":2007,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; Hamilton Health Sciences; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Topotecan; Carboplatin; Internal medicine; Randomized controlled trial; Vincristine; Oncology; Lung cancer; Guideline; Chemotherapy; Cyclophosphamide; Surgery; Cisplatin; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1023224194657993,"gpt":0.576323181801895,"spread":0.4740007623360958,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.01055031,0.0004766721,0.008196913,0.0004449,0.000085291,0.00002199812,0.0003514141,0.0004520409,0.00004916946],"category_scores_gemma":[0.007079933,0.0002943296,0.000885375,0.0004154335,0.0001138248,0.0001033045,0.00009723024,0.001241025,0.000003885267],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002084292,"about_ca_system_score_gemma":0.003656841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001305321,"about_ca_topic_score_gemma":0.000009774541,"domain_scores_codex":[0.9944682,0.001019894,0.003182021,0.0003400785,0.0005059899,0.0004838463],"domain_scores_gemma":[0.9875963,0.004474671,0.005103148,0.0004266282,0.002070161,0.0003290304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004193796,0.0001364909,4.198086e-7,0.6843728,0.001883586,0.0002380907,0.00006455158,5.403945e-8,7.756171e-7,0.000001917923,0.0549998,0.2578821],"study_design_scores_gemma":[0.0006136263,0.001093159,8.70324e-8,0.3591484,0.04066771,0.004102558,0.00005306034,0.00000229793,9.169513e-7,0.000003256113,0.5941817,0.0001332206],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[3.043426e-7,0.9789378,0.0007363338,0.01159537,0.0004815449,0.007164213,0.00002595242,0.00001416006,0.001044322],"genre_scores_gemma":[9.803473e-8,0.9698467,0.02085362,0.0058875,0.000957658,0.0004019682,0.000009937261,0.00009088244,0.001951668],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.5391819,"threshold_uncertainty_score":0.9999509,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2020966893","doi":"10.1371/journal.pone.0071670","title":"Genomic Deregulation of the E2F/Rb Pathway Leads to Activation of the Oncogene EZH2 in Small Cell Lung Cancer","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"EZH2; Cancer research; PRC2; Oncogene; Biology; Gene knockdown; E2F; DNA methylation; Carcinogenesis; Methylation; Cell cycle; Cancer; Cell culture; Gene; Genetics; Gene expression","retraction":null,"screen_n_in":null,"score":{"opus":0.04963951948847328,"gpt":0.2844435283209572,"spread":0.2348040088324839,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001311852,0.00007963764,0.0002112675,0.00006178152,0.00003808897,0.000004143981,0.0001456246,0.00004050302,0.00009929024],"category_scores_gemma":[0.0001380324,0.00004684697,0.00004503317,0.0002892869,0.00005681241,0.00004102262,0.0001316702,0.0001282727,0.000004982143],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000358552,"about_ca_system_score_gemma":0.0002144336,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001893724,"about_ca_topic_score_gemma":0.00063177,"domain_scores_codex":[0.9990956,0.00006142709,0.0002141119,0.0001350615,0.0003297616,0.0001640004],"domain_scores_gemma":[0.9992413,0.00006649809,0.0001134714,0.0003290466,0.0002143365,0.00003537926],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00003762647,0.0002071554,0.2666985,0.0003196322,0.00006054497,6.906824e-8,0.0009121613,0.0001136233,0.7308152,0.000007986949,0.0001811212,0.0006463882],"study_design_scores_gemma":[0.0003651709,0.00004083188,0.4313129,0.0003838736,0.00003857901,5.48402e-8,0.00004700475,0.0002942451,0.5674518,0.00002139013,0.0000147572,0.00002945091],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992889,0.0003865636,0.000008274923,0.004217469,0.00002993996,0.001522479,0.000008224549,0.000007015538,0.0009309709],"genre_scores_gemma":[0.997896,0.00007020636,0.0002196549,0.0001879976,0.00007879916,0.0002009572,0.000001642794,0.00001477153,0.001329998],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1646144,"threshold_uncertainty_score":0.2862757,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1966470979","doi":"10.1016/j.radonc.2011.08.042","title":"Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer","year":2011,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Saint John Regional Hospital","funders":"","keywords":"Medicine; Prophylactic cranial irradiation; Chemotherapy; Radiation therapy; Conventional PCI; Esophagitis; Lung cancer; Stage (stratigraphy); Progressive disease; Surgery; Internal medicine; Disease; Myocardial infarction; Reflux","retraction":null,"screen_n_in":null,"score":{"opus":0.1000356270736468,"gpt":0.4671124100686659,"spread":0.3670767829950192,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000992591,0.0002360954,0.001023775,0.0001582655,0.0001014996,0.000008537962,0.000134612,0.0003086523,0.0004697593],"category_scores_gemma":[0.0001129574,0.0001892443,0.0002492383,0.0001320149,0.0005023946,0.00006404975,0.00001749199,0.0002641637,5.789634e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00039363,"about_ca_system_score_gemma":0.000715277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002266778,"about_ca_topic_score_gemma":0.0001123564,"domain_scores_codex":[0.9980263,0.0002833083,0.0006532376,0.0004645904,0.000170724,0.0004018449],"domain_scores_gemma":[0.998052,0.0006998511,0.0003427802,0.0003292946,0.000396262,0.000179798],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4658209,0.002628088,0.05041298,0.001109347,0.002459967,0.00005102829,0.01031225,0.000003615163,0.04556306,0.000460761,0.005819002,0.415359],"study_design_scores_gemma":[0.4447345,0.07107034,0.05321226,0.0003063545,0.0008180516,0.00007602404,0.001288074,0.002923893,0.03182793,0.0002072028,0.3925748,0.0009605237],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9607826,0.02340063,0.006762812,0.002761815,0.0008378128,0.004198067,0.00006731215,0.00005853008,0.001130387],"genre_scores_gemma":[0.5231118,0.3273268,0.1122921,0.02062891,0.005106995,0.002212532,0.00007273547,0.0003369828,0.008911071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4376708,"threshold_uncertainty_score":0.7717159,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3188488521","doi":"10.6004/jnccn.2020.7796","title":"Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"Xiangya Hospital, Central South University; Central South University; National Natural Science Foundation of China","keywords":"Durvalumab; Medicine; Etoposide; Oncology; Chemotherapy; Lung cancer; Cost-effectiveness analysis; Internal medicine; Cost effectiveness; Stage (stratigraphy); Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1077639222556304,"gpt":0.4199083928252948,"spread":0.3121444705696644,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003966047,0.0002046294,0.001016309,0.0002196066,0.0001101886,0.00001221091,0.0002577148,0.00006374373,0.0001219319],"category_scores_gemma":[0.0001324418,0.0001166728,0.0006262414,0.001909257,0.0001636334,0.00004868999,0.00005502431,0.0002833832,1.635451e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001849593,"about_ca_system_score_gemma":0.001332968,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003647015,"about_ca_topic_score_gemma":0.0008310743,"domain_scores_codex":[0.9974191,0.0003839592,0.0006416184,0.0002062716,0.001092032,0.0002569791],"domain_scores_gemma":[0.9930056,0.001360817,0.0007723193,0.0002423178,0.004561151,0.00005783801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.002872528,0.0005149324,0.1415136,0.000415608,0.007686873,0.00005830424,0.002022766,0.8388548,0.002014201,0.00005959391,0.002660153,0.001326626],"study_design_scores_gemma":[0.0100105,0.0005164151,0.9486731,0.001107377,0.002926059,0.00002610352,0.0005947748,0.01285178,0.008809582,0.0001139637,0.01420311,0.0001672635],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.917766,0.07312397,0.0001518633,0.006810514,0.0005371597,0.001187297,0.0001486625,0.000003724391,0.0002708309],"genre_scores_gemma":[0.9819421,0.01541125,0.0001125371,0.001501319,0.0006531602,0.000115193,0.000007929053,0.00001939204,0.0002370778],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.826003,"threshold_uncertainty_score":0.4836621,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2095839943","doi":"10.1634/theoncologist.2009-0298","title":"Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Chemoradiotherapy; Stage (stratigraphy); Oncology; Current (fluid); Lung cancer; Internal medicine; Cancer; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1446174652254063,"gpt":0.4771418083636698,"spread":0.3325243431382635,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004812404,0.0008049084,0.003060082,0.0001490854,0.0002967784,0.0000666335,0.0006713819,0.0003867421,0.0003372088],"category_scores_gemma":[0.00008105391,0.00039418,0.0008650989,0.0004049182,0.0006401873,0.00002580726,0.0001701487,0.00154675,0.00009808387],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00424088,"about_ca_system_score_gemma":0.002921937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007396706,"about_ca_topic_score_gemma":0.0005618329,"domain_scores_codex":[0.9971324,0.0002724756,0.0006215947,0.0007166481,0.0004378122,0.0008191082],"domain_scores_gemma":[0.9971616,0.0006149225,0.0005129437,0.001332679,0.0001041442,0.0002737207],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005761911,0.0004790577,0.0001586623,0.01373028,0.0006233564,0.00009389944,0.0002202671,8.448955e-7,0.000002735458,0.00004497292,0.01171208,0.9728763],"study_design_scores_gemma":[0.001363732,0.0006495574,0.00002832804,0.004113937,0.002741555,0.00003485363,0.00002054094,0.00001664339,0.00001657425,0.000003196079,0.9906451,0.0003660548],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005373179,0.9831479,0.000006941882,0.001199862,0.00124672,0.00499349,0.0002502806,0.0001597141,0.008941378],"genre_scores_gemma":[0.000006687213,0.9726223,0.0001045243,0.0001377343,0.002009457,0.003428889,0.0001206214,0.0001211188,0.02144867],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.978933,"threshold_uncertainty_score":0.999851,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}